27results about How to "Improve heart function" patented technology

The invention discloses application of an AXL inhibitor in preparation of a medicine for treating heart failure, and relates to the field of pharmacy. The invention provides application of an AXL inhibitor in a medicine for treating heart failure. The AXL inhibitor can remarkably inhibit abnormal activation of fibroblasts and can remarkably improve the heart function of a mouse with heart failure.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention discloses an application of rilpivirine (RPV) in preparation of a medicine for treating myocardial infarction, and relates to the field of medicines for treating myocardial infarction. The invention belongs to the technical field of biological medicine. According to the present invention, the acute myocardial infarction (AMI) disease mouse model is constructed through the induction of the permanent ligation of the left anterior descending branch; after rilpivirine is orally taken, the conditions of survival, heart function, structure change and the like of the AMI mouse model during X weeks after operation are observed. Results show that rilpivirine (as shown in the formula I) has the effects of remarkably improving the cardiac function of AMI injury, relieving cardiac remodeling and increasing the survival rate of AMI mice. Therefore, a new technical means is provided for treatment of myocardial infarction, and rilpivirine has a wide application prospect in treatment of myocardial infarction diseases. # imgabs0 #

The invention discloses 4-octyl itaconic acid liposome loaded nano-particles wrapped by a metal-phenolic aldehyde network coating. The nano-particles are used for adjusting a myocarditis microenvironment after acute myocardial infarction. The drug-loaded nanoparticle provided by the invention can be divided into a drug-loaded liposome inner core and a shell layer; the inner core is functionalized liposome nanoparticles loaded with 4-octyl itaconic acid, and the shell layer is a metal-phenolic network coating formed by self-assembly of tannic acid and Mn < 2 + >. The invention further provides application of the drug-loaded nanoparticles in preparation of drugs for treating inflammation causing myocardial injury. The tannic acid of the shell layer of the drug-loaded nanoparticle has high affinity to an extracellular matrix of cardiac muscle tissue, and the drug-loaded nanoparticle injected from caudal vein can be efficiently enriched to a myocardial injury area to play roles in inhibiting pyroptosis of cardiac muscle cells, regulating macrophage functions and remodeling a damaged myocarditis microenvironment; accurate, effective and safe acute myocardial infarction treatment is achieved.

An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin I2 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin I2 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.

The invention discloses an application of a high mobility group protein B2 (HMGB2) in regeneration and repair of cardiac muscle after myocardial injury, and belongs to the technical field of biomedicine. Test results show that by overexpressing HMGB2 protein in myocardial cells, the in-vitro myocardial cell proliferation capacity is remarkably enhanced, and meanwhile, after acute myocardial ischemia injury in vivo, the myocardial cells can quickly start endogenous myocardial regeneration to play roles in promoting myocardial regeneration and repair, reducing scar formation, improving cardiac functions and the like. Besides, the invention designs a drug delivery mode based on a virus vector carrying HMGB2 gene, the problems of poor targeting, low biological safety, low treatment efficiency and the like of a traditional treatment method are solved, a new drug action target is provided for prevention and treatment of acute myocardial infarction and myocardial ischemia-reperfusion injury, and the drug delivery system has important clinical transformation value.

The invention discloses the use of Xinshubao tablets in preparing drugs for preventing and / or treating heart failure. Animal experiments prove that Xinshubao tablets can significantly prevent and treat heart failure by improving cardiac function and reducing cardiac fibrosis. Xinshubao tablets are applied to heart failure, especially to the prevention and treatment of heart failure with mildly reduced ejection fraction or heart failure with reduced ejection fraction, and have broad application prospects.

The invention relates to the field of biological medicines, and particularly discloses application of hydroxychloroquine in preparation of medicines for preventing and treating immune myocarditis, inflammatory cardiomyopathy and complications thereof. Immune myocarditis is caused by immune response caused by infectious or non-infectious diseases, and inflammatory cardiomyopathy is cardiomyopathy caused by chronic myocarditis. The hydroxychloroquine can reduce chemotaxis from inflammatory cells to the heart, inhibit macrophages from generating chemotactic factors CXCL16 and infiltration of Th17 cells, NKT cells and T lymphocytes, inhibit cardiac inflammatory response, fibrosis and cardiac function damage, and improve cardiac remodeling and ventricular dilatation. Hydroxychloroquine can significantly reduce cardiovascular composite endpoint events of patients with inflammatory cardiomyopathy, improve cardiac functions of the patients, and reduce hs-cTnI, NT-proBNP, hs-CRP and levels of various plasma inflammatory factors. Clinical and basic research results show that the hydroxychloroquine can be used for treating and / or preventing human immune myocarditis and inflammatory cardiomyopathy, and has the potential of being developed into the medicine for clinically preventing and treating immune myocarditis and inflammatory cardiomyopathy.

The invention relates to the technical field of pharmaceutical preparations, in particular to a traditional Chinese medicine compound and preparation for treating coronary heart disease and a preparation method and application of the traditional Chinese medicine compound and preparation. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 10-30 parts of astragalus membranaceus, 5-15 parts of rhodiola rosea, 10-30 parts of salvia miltiorrhiza, 5-15 parts of ligusticum wallichii, 10-30 parts of trichosanthes kirilowii maxim, 5-15 parts of allium macrostemon, 5-15 parts of folium ginkgo, 10-30 parts of radix puerariae, 10-30 parts of radix ophiopogonis, 3-10 parts of schisandra chinensis, 15-30 parts of oyster, 5-15 parts of cassia twig and 3-10 parts of liquorice. Animal experiment results show that the traditional Chinese medicine composition provided by the invention has remarkable and multi-aspect curative effect advantages in the aspect of treating a coronary heart disease rat model. The traditional Chinese medicine composition not only can enhance myocardial contractility and recover heart blood pumping function, but also can inhibit inflammatory response, relieve myocardial damage, effectively relieve myocardial structure damage and protect myocardial tissue integrity. In addition, a proportional experiment result shows that the effect of the composition provided by the invention can be obviously weakened by losing any medicine pair, so that all the medicines in the formula cannot be absent.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The invention belongs to the technical field of medicines, and particularly relates to application of a CCNL1 inhibitor in preparation of a medicine for treating cardiomyopathy, and the amino acid sequence of CCNL1 is as shown in SEQ ID NO.1. It is found that by knocking down expression of CCNL1, DOX-induced myocardial cell apoptosis can be inhibited, DOX-induced myocardial cell ROS production can be inhibited, the lipid peroxidation level in DOX-induced myocardial cells can be reduced, and DOX-induced myocardial mitochondrial damage can be inhibited, so that application of the CCNL1 inhibitor in preparation of drugs for treating cardiomyopathy is provided.

The invention discloses an application of a neuron-derived neurotrophic factor NDNF in promotion of regenerative repair and functional reconstruction of an injured heart, particularly relates to an application of the NDNF in a medicine for treating or improving the injured heart, a recombinant vector and a medicine, and belongs to the technical field of biological medicines. The invention provides application of NDNF in promotion of regenerative repair and functional reconstruction of damaged heart. The invention proves that the medicine prepared from the NDNF can be used for treating or improving the insufficiency and inflammation of the damaged heart, and particularly has a good treatment effect on the damaged heart caused by myocardial infarction, and the treatment effect specifically comprises the effect of reducing myocardial cell apoptosis and inflammation after myocardial infarction and the effect of inhibiting myocardial cell pathological hypertrophy after myocardial infarction due to overexpression of the NDNF. In addition, overexpression of the NDNF can also promote proliferation of myocardial cells after myocardial infarction.

Provided is a valve implantation device with the assistance of a heart isolation device, which includes a valve, a heart isolation device, and a valve connection device, wherein the heart isolation device includes an isolation device body; the isolation device body is provided with a positioning part; the isolation device body is fixed on a heart tissue through the positioning part; the valve connection device includes a first connection part; one side of the first connection part is connected with the valve; the isolation device body is provided with a second connection part; and the first connection part and the second connection part are connected during use. The device of the present disclosure can improve the cardiac function before / during valve implantation and increases the effectiveness of an operation. Fixing the valve by the hook-type structure can reduce metal objects required for replacement and avoid potential injury to a heart valve structure. A connector structure connected to the valve stably locates the valve and accurately releases the height of the valve, so that paravalvular leak and injury to a valve annulus plane can be prevented.

A surgical annulus, a mechanical valve, and a surgical biovalve are disclosed. The three cardiac surgical valve instruments preferably adopt a high valve ring or short valve angle design. By means of the high-valve-ring surgical valve ring, left ventricular outflow tract obstruction can be avoided during a mitral valve intervention operation in the future. A mechanical valve and a surgical bioprosthetic valve move up a leaflet fixing structure and leaflets through a high annulus or short valve angle design to retain leaflets and subvalvular structures as much as possible in future mitral and tricuspid valve operations to facilitate post-operative heart function improvement.

The invention provides a pharmaceutical composition for resisting chronic heart failure as well as a preparation method and application thereof, and belongs to the technical field of medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: radix aconiti lateralis preparata, semen lepidii, poria cocos, rhizoma atractylodis macrocephalae, radix paeoniae alba, fresh ginger, rhizoma alismatis, peach kernels, flos carthami, radix salviae miltiorrhizae, radix angelicae sinensis, rhizoma chuanxiong, radix achyranthis bidentatae, radix bupleuri, fructus aurantii, radix platycodonis, radix astragali, fructus jujubae and radix glycyrrhizae preparata. The prepared pharmaceutical composition for resisting chronic heart failure is simple in preparation method and good in treatment effect, has very good effects of regulating vascular tension, myocardial contractility and heart remodeling, inhibits ferroptosis of myocardial cells so as to protect myocardial cells from being damaged and prevent heart failure, and is small in side effect, high in patient compliance and free of toxic and side effects. Wide application prospects are realized.

The invention belongs to the field of biological medicine, and particularly relates to application of pazufloxacin mesylate to preparation of medicine for treating acute myocardial infarction. The invention provides an application of pazufloxacin or a pharmaceutically acceptable salt thereof in preparation of a product for preventing and / or treating myocardial infarction, and further provides an application of pazufloxacin or a pharmaceutically acceptable salt thereof in preparation of a product for preventing and / or treating heart diseases, and the heart diseases are caused by acute myocardial infarction. The pazufloxacin or the pharmaceutically acceptable salt of the pazufloxacin is pazufloxacin mesylate. It is found for the first time that pazufloxacin mesylate can be applied to preparation of the medicine for treating acute myocardial infarction or heart diseases caused by acute myocardial infarction, and a new treatment approach is provided for treating acute myocardial infarction or acute myocardial infarction related diseases.

The invention discloses a screening method of a traditional Chinese medicine monomer composition for resisting heart failure. The method comprises the following steps: 1, carrying out water extraction and enrichment on astragalus membranaceus and monkshood to obtain astragalus membranaceus and monkshood soup enriched components; 2, synthesizing myocardial mitochondrial membrane coated magnetic beads and myocardial lysosome membrane coated magnetic beads; 3, gathering enriched components of the astragalus mongholicus-monkshood decoction, and carrying out ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry to obtain components of songorine, neoline, calycosin and formononetin as traditional Chinese medicine monomer composition; the traditional Chinese medicine monomer composition is prepared by dissolving songlin, neoline, calycosin and formononetin in a sodium carboxymethyl cellulose solution. The synthesized myocardial mitochondrial membrane coated magnetic beads and the myocardial lysosome membrane coated magnetic beads are used for adsorbing and identifying active ingredients in the astragalus mongholicus-monkshood decoction, the effective ingredient composition for resisting heart failure is successfully screened, and the preparation method is simple and easy to implement; the traditional Chinese medicine monomer composition plays a role in preparing anti-heart-failure medicines by improving heart functions and the like.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

The application discloses a new application of a substance increasing the content or activity of PARKIN in treating and / or preventing cardiovascular diseases. The application proves by transgenic and gene therapy means that increasing the content of PARKIN can significantly inhibit the activation of a cGAS-STING signal pathway and the downstream inflammatory response, thereby significantly improving the heart function, reducing the myocardial inflammatory response and myocardial fibrosis. The application provides a new drug target and treatment strategy for the prevention and treatment of cardiovascular diseases, and has important clinical application value.

The present invention relates to the technical field of application of circRNADhx9 (circDhx9), and specifically, discloses the application of CircDhx9 as a molecular target in the treatment of myocardial ischemia-reperfusion injury, and relates to the use of circDhx9 as a molecular target for the treatment of myocardial ischemia-reperfusion injury, which belongs to the technical field of biomedicine. The present invention designs a shRNA that can knock down the expression of circDhx9, and constructs an adeno-associated virus vector HBAAV2 / 9‑circDhx9shRNA‑EGFP of shRNA. It has been detected that circDhx9 is significantly upregulated in the heart after myocardial ischemia-reperfusion. The shRNA adeno-associated virus vector prepared by the present invention can effectively reduce the expression of circDhx9 in the mouse heart, thereby reducing the myocardial infarction area of ​​myocardial ischemia-reperfusion mice, improving cardiac function, and realizing the use of circDhx9 to treat myocardial ischemia-reperfusion injury. The present invention provides an important supplement to the biological function of circDhx9, provides an effective treatment for myocardial ischemia-reperfusion injury, and also provides a theoretical basis for the application of circDhx9 as a molecular target in the treatment of myocardial ischemia-reperfusion injury.

The invention provides a traditional Chinese medicine composition for treating coronary heart disease as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 4-18 parts of ginseng, 7-28 parts of trichosanthes kirilowii maxim, 7-28 parts of allium macrostemon, 4-18 parts of pinellia ternate, 7-28 parts of radix paeoniae rubra, 7-28 parts of ligusticum wallichii and 4-18 parts of radix scrophulariae. The traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving the heart function, reducing the blood fat level and improving myocardial injury for model rats with the syndrome of phlegm and blood stasis in coronary heart disease.

The invention discloses application of tamibarotene in preparation of a medicine for preventing and treating myocardial infarction, the tamibarotene can be directly combined to an NACHT structural domain of NLRP3 in a targeting manner, the ATP enzyme activity of the NLRP3 is inhibited, the assembly of NLRP3 inflammasome is inhibited, the activation of the NLRP3 inflammasome is effectively prevented, and the tamibarotene has a remarkable prevention and treatment effect on the myocardial infarction.

This invention discloses a traditional Chinese medicine composition for treating coronary heart disease and depression, its application, and preparation method. The traditional Chinese medicine composition comprises the following components by weight: 10-15 parts of Salvia miltiorrhiza; 8-12 parts of Panax ginseng; 8-12 parts of Ligusticum chuanxiong; 8-12 parts of Trichosanthes kirilowii; 8-12 parts of Paeonia lactiflora; 6-10 parts of Cyperus rotundus; 6-10 parts of Curcuma longa; 8-12 parts of Acanthopanax senticosus; 6-10 parts of Morinda officinalis; and 4-8 parts of Cinnamomum cassia. The preparation method includes: (1) Weighing each Chinese medicinal material according to the proportion of Chinese medicine, cleaning and crushing it appropriately; (2) First decoction: Add 3 times the weight of drinking water to the medicinal material, soak for 30 minutes, then heat to boiling, turn to low heat and keep boiling, continue to decoct for 30 minutes, filter and collect the filtrate; (3) Second decoction: Add 3 times the weight of drinking water to the dregs again, heat to boiling in the same way, turn to low heat and decoct for 30 minutes, filter and collect the filtrate; (4) Combine the filtrates obtained in steps (2) and (3), heat and concentrate them over low heat, and finally make a medicinal liquid with a total volume of 100 mL.

The application discloses a kind of composition and its application in preparation with improved cardiac function product.The composition described herein, comprising the following components: (1) beta-nicotinamide mononucleotide or 1,6-fructose diphosphate tri-sodium salt, and (2) coenzyme Q 10 And vitamin complex.The composition described herein, beta-nicotinamide mononucleotide or 1,6-fructose diphosphate tri-sodium salt is combined with coenzyme Q 10 And vitamin complex, the composition obtained after combination has good prevention or treatment heart failure effect and the effect of improving cardiac function.Therefore, the composition described herein is used as active ingredient for preparing dietary supplement, health product or drug with prevention or treatment heart failure effect or with improving cardiac function, has important application value.

The invention discloses an application of MFAP5 and an adeno-associated virus vector carrying MFAP5-siRNA in myocardial injury repair treatment drugs, and belongs to the field of medical biology, the repair process after myocardial injury can be remarkably promoted by knocking down expression of an MFAP5 gene, after the MFAP5 gene is knocked down, the cardiac function after myocardial infarction can be improved, fibroblast proliferation and migration can be inhibited, and the myocardial injury repair treatment effect can be improved. Further, the myocardial injury repair is realized. Regulation of MFAP5 gene expression is expected to become an effective strategy for relieving heart failure progression after ischemic myocardial injury.

This invention provides the application of ZBP1 or its encoded protein in the preparation of products for diagnosing septic cardiomyopathy, relating to the field of biomedical technology. Transcriptome sequencing analysis of a septic cardiomyopathy model revealed the activation of multiple programmed cell death-related pathways. Further screening using the intersection of differentially expressed genes and pan-apoptotic gene sets identified ZBP1, which showed an upregulated trend in the model. Validation was achieved through an in vivo cardiomyocyte-specific ZBP1 gene knockout model and in vitro cardiomyocyte knockdown experiments. Results showed that regulating ZBP1 expression can affect the expression of multiple programmed cell death-related molecules and is associated with myocardial injury and inflammatory responses. This invention suggests that ZBP1 may participate in the pan-apoptotic process and provides a novel potential molecular target for septic cardiomyopathy.

The invention relates to the technical field of myocardial infarction treatment, and particularly discloses a method for improving heart failure after myocardial infarction by cold air inhalation, which comprises the following steps: step 1, selecting a plurality of mice for experiments, and placing the mice for experiments in an experiment area; 2, preparing air for the laboratory mouse to inhale; 3, sucking the prepared air into the experimental mouse; and 4, observing the mouse which inhales the air and is used for the experiment. Air inhalation at a proper temperature is given to the myocardial infarction mouse through the air inhalation device, so that the lifetime of the myocardial infarction mouse can be obviously prolonged, the cardiac function and the myocardial infarction area of the myocardial infarction mouse can be improved, and the cardiac sympathetic nerve activity of the myocardial infarction mouse can be reduced; air inhalation at a proper temperature can be used as a new means for improving prognosis of patients with myocardial infarction, and a new thought and method can be provided for treating or preventing heart failure after myocardial infarction.